EKTA.B

56.95

+3.36%↑

EKTA.B

56.95

+3.36%↑

EKTA.B

56.95

+3.36%↑

EKTA.B

56.95

+3.36%↑

EKTA.B

56.95

+3.36%↑

Home・Akciju saraksts・Orexo AB

O
Orexo AB

Slēgts

19.92 0.2

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.7

Max

20.4

Galvenie mērījumi
By Trading Economics
Ienākumi	-68M -116M
Pārdošana	-115M 3.3M
EPS	20.884
Peļņas marža	-3,503.03
Darbinieki	72
EBITDA	-262M -272M

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-262M 772M
Iepriekšējā atvēršanas cena	19.72
Iepriekšējā slēgšanas cena	19.92

Orexo AB Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. apr. 23:25 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026. g. 13. apr. 22:45 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026. g. 13. apr. 18:03 UTC

Peļņas

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026. g. 13. apr. 23:58 UTC

Peļņas

Review & Preview: Earnings Time -- Barrons.com

2026. g. 13. apr. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026. g. 13. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026. g. 13. apr. 23:20 UTC

Tirgus saruna

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026. g. 13. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026. g. 13. apr. 21:26 UTC

Galvenie ziņu notikumi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 13. apr. 21:16 UTC

Peļņas

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026. g. 13. apr. 19:59 UTC

Tirgus saruna

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026. g. 13. apr. 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026. g. 13. apr. 19:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Precious Metals Market Talk on April 9

2026. g. 13. apr. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026. g. 13. apr. 18:43 UTC

Tirgus saruna

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Salīdzinājums

Cenas izmaiņa

Orexo AB Prognoze

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Citi krājumi no sektora

EKTA.B

Elekta AB

56.95

↑ +3.36%

O Orexo AB

Pārskats

Akcijas cenas izmaiņa

Galvenie mērījumi

Dividendes

Tirgus statistika

Orexo AB Grafiks

Saistītās ziņas

Salīdzinājums

Orexo AB Prognoze

Finanšu rādītāji

Par Orexo AB

Citi krājumi no sektora

O
Orexo AB